Table 2. Recommendations of prostate cancer screening of specialty societies.
| Specialty society | Screening recommendations |
|---|---|
| American Urological Association - AUA (2013) | <40y or >70r or <10-15r de LE: do not screen |
| 40-54y: offer screening if with high risk1 | |
| 55-69y: offer screening | |
| European Association of Urology - EAU (2015) | Men>50 years old |
| Men>45 year + familial history | |
| African-Americans | |
| PSA>1ng/mL at 40 years old | |
| PSA>2ng/mL at 60 years old | |
| American Cancer Society - ACS (2015) | >50 years + LE >10 yeqrs |
| >45 years + high risk1 | |
| >40 years + very high risk2 | |
| Sociedade Brasileira de Urologia - SBU (2013) | >50 years |
| >45 years + high risk1 | |
| Consenso Nacional Inter - Sociedades (2014) – Argentina | <40y or >70y + comorbidities: do not screen |
| 40-55y: if with high risk | |
| 55-70y or >70y without comorbidities: shared decision | |
| Sociedad Colombiana de Urologia (2013)* | Organized population screening not recommended |
| Early opportunity detection if >50u or <50y + risk factors | |
| Frequency ≥5 years. | |
| Sociedad Peruana de Urología | >50 years |
| >40 years + high risk1 | |
| Sociedad Mexicana de Urologia | >45 years |
*
Ministerio de Salud and Sociedad de Urologia de Colombia recommendations
LE = Life expectancy
1
High risk: 01 first-degree relative with prostate cancer or African-american
2
Very high risk: >01 frst-degree relative with prostate cancer